Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR103
- Development stage
- Phase 2
- Lead developer
- Immune Response Corporation
- Modality
- Vaccines & Immunotherapeutics
01
Overview
IR103 is a code name for a combination drug consisting of Remune (an HIV-1 immunogen) and Amplivax. This combination is being investigated in a Phase III clinical trial for its safety and efficacy in treating HIV/AIDS. The primary objective of the treatment is to reduce HIV viral load and improve immune cell counts, specifically White Blood Cells (WBC), CD4+ T cells, and CD8+ T cells, thereby increasing HIV immunity. It functions as a vaccine-based approach to stimulate the immune system against HIV-1.
- Brand names
- Remune + AmplivaxREMUNEX
- Other names
- HIV-1 immunogen + AmplivaxIR103 REMUNE + AMPLIVAX
02
Targets
TLR9 (Toll-like receptor 9)HIV (HIV-1 enzymes)
Beyond the preview
Go deeper on IR103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR103.